Panadol 500mg tablets film-coated

Riik: Armeenia

keel: inglise

Allikas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Laadi alla Toote omadused (SPC)
27-05-2015

Toimeaine:

paracetamol

Saadav alates:

S.C. Europharm S.A.

ATC kood:

N02BE01

INN (Rahvusvaheline Nimetus):

paracetamol

Annus:

500mg

Ravimvorm:

tablets film-coated

Ühikuid pakis:

(12/1x12/) blister

Retsepti tüüp:

OTC

Volitamisolek:

Registered

Loa andmise kuupäev:

2015-05-15

Toote omadused

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Panadol Tablet
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Paracetamol 500.0 mg
3.
PHARMACEUTICAL FORM
Film-coated tablets
White, film-coated and capsule-shaped tablets with flat edges with
PANADOL embossed
on one side and a break line on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic therapy of pain: headache (including migraine and tension
headache,
toothache, sore throat, backache, muscle and rheumatic pains,
dysmennorhoea, and for
relieving the fever (as antipyretic). In case of increased body’s
temperature associated with
cold and flu. Medicine is intended for pain decrease at the time of
using and has no
influence for progressive disease.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Oral administration only.
Adults (including the elderly) and children over 12 years aged: 1-2
tablets taken every
4 to 6 hours as required. Minimum dosing interval: 4 hours. Maximum
daily dose: 8 tablets
(4000 mg).
Children, 6 to 12 years: ½-1 tablet taken every 4 to 6 hours as
required. Minimum dosing
interval: 4 hours. Maximum daily dose: 4 tablets. Maximum daily dose:
60mg/kg presented
in divided doses of 10 – 15 mg/kg throughout the 24 hour period.
Maximum duration of continued use without medical advice: 3 days.
4.3
CONTRAINDICATIONS

Hypersensitivity to paracetamol or any of the other constituents;

Children under the age of 6 years.
Care is advised in the administration of paracetamol to patients with
renal or hepatic failure,
benign hyperbilirubinemia (including Gilber’s syndrome), virus
hepatitis, hereditary
absence of glucose-6-phosphate dehydrogenase, alcohol-induced liver
failure, alcohol
dependence, the elderly age, during pregnancy and lactation.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients who have been diagnosed with liver or kidney impairment must
seek medical
advice before taking this medication.
Do not exceed the stated dose.
Do not take with any other paracetamol - containing 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik vene 27-05-2015